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Abstract
Background Dense fibrin networks resistant to lysis have been reported in patients at high risk of thromboembolism. Little 
is known about fibrin clot properties in cancer. We investigated fibrin clot properties and their determinants in patients with 
inoperable lung cancer.
Methods We enrolled 150 patients with advanced lung cancer prior to therapy and 90 control subjects matched by age, 
sex, cardiovascular disease, and diabetes. Plasma clot permeability  (Ks), turbidimetric analysis of clot formation, clot lysis 
time (CLT), microparticle-associated tissue factor (MP-TF) activity, thrombin generation, and serum cotinine levels were 
determined.
Results Lung cancer patients, compared with controls, formed at a faster rate (− 8.1% lag phase) denser plasma fibrin 
networks (− 27.2%  Ks) that displayed impaired lysis (+ 26.5% CLT), along with 19.5% higher MP-TF activity and 100% 
higher peak thrombin generated, also after adjustment for potential confounders. Cotinine levels were associated with fibrin 
maximum absorbance (r = 0.20, p = 0.016) and  Ks (r = − 0.50, p < 0.0001) in cancer patients. On multivariate regression 
analysis, an increase in cotinine levels was a predictor of low  Ks (the lower quartile, < 5.8 × 10−9  cm2; odds ratio = 1.21 per 
10 ng/ml, 95% confidence interval 1.02–1.46), but not CLT.
Conclusion Advanced lung cancer is associated with the prothrombotic plasma clot phenotype largely driven by smoking.
Keywords Clot lysis time · Fibrin clot · Lung cancer · Smoking · Thrombin generation
Introduction
Lung cancer is the leading cause of cancer death worldwide 
[1]. The 5-year survival rate for stage IIIA, IIIB, and IV non-
small-cell lung cancer (NSCLC) is about 14%, 5%, and 1%, 
respectively [2], while 5-year survival rates for stage II, III, 
and IV small-cell lung cancer (SCLC) are 19%, 8%, and 2%, 
respectively [3]. Current treatment strategies significantly 
prolong the life of patients with advanced lung cancer [4].
Venous thromboembolism (VTE) associated with a 50% 
higher risk of death occurs in approximately 3% of lung 
cancer patients [5, 6]. The 1-year cumulative incidence of 
VTE is 10.2% in SCLC [7] and 22% in NSCLC patients 
[8]. Chemotherapy is associated with threefold higher risk 
for VTE in lung cancer patients [9]. Moreover, lung can-
cer increases the stroke risk [10]. Cardiovascular disease 
observed in 23% of lung cancer patients increases the mor-
tality for stages I–IIIB [11].
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Elevated thrombotic risk in patients with malignancy 
depends on multiple factors, including the type of cancer, 
its clinical stage and grade, concomitant diseases, and treat-
ment [12]. Prothrombotic abnormalities in lung cancer 
involve elevated fibrinogen [12], thrombin generation [13], 
expression of tissue factor (TF) [14], plasminogen activa-
tor inhibitor-1 and -2 [15], cancer procoagulant [13], and 
impaired activation of the protein C pathway [16]. Increased 
TF expressing microparticles (MPs) associated with VTE 
were found in lung cancer and metastatic pancreatic cancer 
[17, 18].
Formation of compact fibrin networks resistant to lysis 
predisposes to VTE [19, 20]. Cigarette smoking also impairs 
fibrin clot properties [21]. Reports on fibrin clot properties 
in cancer patients are limited [22, 23]. Recently, we have 
shown that a 3-month chemotherapy improves fibrin clot 
properties in lung cancer patients [24]. To our knowledge, 
fibrin clot properties and their determinants in patients with 
advanced lung cancer before chemotherapy have not been 
investigated yet.
Materials and methods
Patients
From May to September 2014, we studied 150 white consec-
utive patients with advanced histologically or cytologically 
confirmed lung cancer who were recruited at the Department 
of Oncology, John Paul II Hospital, Cracow, Poland [24]. 
Patients were categorized into subjects with SCLC and those 
with NSCLC that included three main subtypes: adenocar-
cinoma, squamous cell cancer, and not otherwise specified 
(NOS) carcinoma, involving cases other than adenocarci-
noma, squamous cell, large cell carcinoma, or mixed/other 
histology.
The American Joint Committee on Cancer (AJCC) stages 
were determined according to the AJCC 7th edition stag-
ing system, using available clinical data. The exclusion 
criteria were any active infections, glomerular filtration 
rate < 60 ml/min, hypo- or hyperthyroidism, any vascular 
events within the preceding 3 months, and current anti-
coagulant therapy. Patients receiving thromboprophylaxis 
with low-molecular-weight heparins (LMWH) were eligible. 
The recommended thromboprophylaxis in high-risk patients 
was administered [25, 26]. Heart failure (HF) was defined 
as the presence of relevant symptoms and signs and left 
ventricular ejection fraction ≤ 45%. Arterial hypertension 
was diagnosed based on a history of hypertension (blood 
pressure > 140/90 mmHg) or preadmission antihyperten-
sive treatment. Diabetes mellitus was defined as fasting 
glucose ≥ 7.0 mM on two separate occasions or use of insu-
lin or oral hypoglycemic agents. Coronary artery disease 
(CAD) was defined as hospitalization for angina, prior docu-
mented myocardial infarction, or coronary revascularization. 
Ischemic stroke was diagnosed based on the World Health 
Organization criteria. Chronic obstructive pulmonary dis-
ease was defined by the presence of irreversible expiratory 
airflow limitation measured by spirometry. A current smoker 
was defined as a subject who has smoked 100 cigarettes and 
currently declares the use of one or more cigarettes per day, 
while former smoker as a person who has smoked at least 
100 cigarettes in a lifetime, but currently (at least within the 
last month) does not smoke.
Control subjects (n = 90) matched for age, sex, cardiovas-
cular disease, and diabetes included members of the hospital 
staff and their family. The Bioethics Committee of the Dis-
trict Medical Chamber in Cracow approved the study (31/
KBL/OIL/2013), and participants provided informed con-
sent in accordance with the Declaration of Helsinki. A writ-
ten informed consent was obtained from all the participants.
Laboratory investigations
Fasting blood samples were drawn from antecubital vein 
using minimal stasis. Blood samples were drawn at the time 
of enrolment before starting therapy. Patients who received 
prophylactic LMWH were drawn at least within 12 h post 
injection. Complete blood count, glucose, and creatinine 
were assayed by routine laboratory techniques. Fibrinogen 
was determined using the Clauss method. Plasma D-dimer 
was measured with the Innovance D-dimer assay (Siemens, 
Marburg, Germany). Immunoenzymatic assays were used 
to determine the TF-bearing MP (MP-TF) activity (Hyphen 
BioMed, Neuville sur Oise, France) and cotinine levels (Cal-
biotech, El Cajon, CA, USA).
Fibrin clot properties
In citrated plasma (vol/vol, 9:1 of 3.2% sodium citrate), 
the following variables describing a plasma clot formation, 
structure, and lysability were determined in duplicate by 
technicians blinded to the origin of the samples (intraassay 
and interassay coefficients of variation, 5–7%).
Clot permeability and scanning electron microscopy
Permeation of plasma fibrin clots was determined as 
described [27]. In brief, 20 mM calcium chloride and 1 U/
mL human thrombin (Sigma-Aldrich, St. Louis, MO, USA) 
were added to citrated plasma. Tubes containing the clots 
were connected to a reservoir of a Tris-buffered saline, and 
its volume flowing through the gels was measured. A perme-
ation coefficient  (Ks), which indicates the pore size, was cal-
culated from the equation: K
s
= Q × L × ∕t × A × Δp , 
where Q is the flow rate in time t, L is the length of a fibrin 
Medical Oncology (2019) 36:37 
1 3
Page 3 of 9 37
gel, η is the viscosity of liquid, t is percolating time, A is the 
cross-sectional area, and Δp is a differential pressure.
After  Ks measurement, clots (n = 6) were fixed using 2.5% 
glutaraldehyde, then removed from tubes, washed with dis-
tilled water, dehydrated in graded water–ethanol solutions, 
dried by the critical point procedure, and sputter coated with 
gold. Samples were scanned in six different areas (micro-
scope JEOL JCM-6000; JEOL Ltd., Tokyo, Japan) at mag-
nification of 5,000x to determine a fibrin diameter of at least 
50 fibers per clot using the ImageJ software (US National 
Institutes of Health, Bethesda, MD, USA).
Turbidity measurements
Plasma citrated samples were mixed 2:1 with a TBS contain-
ing 0.6 U/mL human thrombin (Sigma-Aldrich) and 50 mM 
 CaCl2 to initiate polymerization. Absorbance was read at 
405 nm with a Perkin-Elmer Lambda 4B spectrophotometer 
(Molecular Devices). The lag phase of the turbidity curve, 
which reflects the time required for initial protofibril forma-
tion and maximum absorbance at the plateau phase (ΔAbs), 
indicating an average fibrin fiber size, fibrin branching, and 
clot density, was recorded [27].
Clot lysis assay
Clot lysis time (CLT) was measured as described previ-
ously [27]. Briefly, to 75 µl of citrated plasma we added TF 
(dilution 105 times; Innovin, Dade Behring, Deerfield, IL, 
USA),  CaCl2 (final concentration, 17 mM), tissue plasmino-
gen activator (tPA, final concentration, 30 U/ml; Boehringer 
Ingelheim, Ingelheim, Germany), and phospholipid vesicles 
[28] (final concentration, 10 mM). HEPES buffer was added 
to make a total volume of 150 µl.
Thrombin generation assay
To assess the thrombin generation profiles, we used the assay 
previously described [29, 30]. In brief, corn trypsin inhibitor 
was added to citrated plasma (0.1 mg/mL, final concentra-
tion) and 80 µL of the sample was mixed with relipidated TF 
(5 pM, final concentration), 2.5 mM Z-GGR-AMC/90 mM 
 CaCl2 solution, and a 120 µM phospholipid vesicles solu-
tion. Hydrolysis of the AMC substrate (at 370/460 nm) 
was followed over a 3600s period. Changes in fluorescence 
were converted to thrombin concentration using a calibra-
tion curve built by sequential dilutions of human thrombin.
Statistical analysis
The study was powered to have a 90% chance of detecting 
a 10% difference in CLT using a P value of 0.01, based 
on the previous study [31]. In order to demonstrate such 
a difference, or a greater one, 32 patients or more were 
required in each group. In turn, to demonstrate such a dif-
ference, or a greater one, in  Ks using a P value of 0.05 at 
least 31 patients were required in each group [28].
Variables were presented as mean and standard devia-
tion, median, and interquartile range or otherwise stated. The 
normality of distribution was checked using Shapiro–Wilk 
test. The Spearman’s rho correlation coefficient was com-
puted to measure the relationship between continuous vari-
ables. For testing association for categorical variables, the 
Fischer’s Exact test was used. The t test or ANOVA were 
used for means comparison, whereas the nonparametric U 
Mann–Whitney or Kruskal–Wallis tests were used for com-
parison of nonnormally distributed variables. For paired 
data, the paired Student’s t test or the Wilcoxon signed-rank 
tests were used as appropriate.
Odds ratios of having the lower quartile for  Ks (≤ Q1 vs. 
> Q1) and the upper quartile for CLT (≥ Q3 vs. < Q3) were 
estimated using multivariate logistic regression. The models 
were adjusted for age, sex, body-mass index, and fibrino-
gen. In the final models, only variables with p values < 0.05 
were retained. All statistical analyses were performed with 
software JMP®, Version 12.2.0 (SAS Institute INC., Cary, 
NC, USA).
Results
Patient characteristics
Baseline characteristics of 150 lung cancer patients and 
90 control subjects are summarized in Table 1. At enrol-
ment 61 (40.7%) patients were diagnosed with the SCLC 
and 89 (59.3%) with the NSCLC. Metastatic lung cancer 
was diagnosed in 92 (61.3%) patients, while in 58 (38.7%) 
locally advanced inoperable lung cancer was recognized. 
The SCLC group included 34 (55.7%) patients with limited 
disease (LD, stage IIIAB) and 27 (44.3%) with extended 
disease (ED, stage IV).
Among NSCLC patients, 27 (30%) individuals had 
metastases to lungs, 10 (11.2%) to the pleura, 9 (10.1%) 
to the liver, 14 (15.7%) to adrenals, 10 (11.2%) to bones, 
10 (11.2%) to the brain, and 10 (11.2%) to other locations. 
In patients with SCLC, lung metastases were present in 4 
(6.6%) patients, metastases to the pleura in 2 (3.3%), to the 
liver in 13 (21.3%), to adrenals in 4 (6.6%), to bones in 8 
(13.1%), to the brain in 2 (3.3%), and to other locations in 
3 (4.9%) patients. Metastasis in more than one location was 
detected in 29 (19.3%) patients. Patients with lung cancer, 
compared with controls, had lower body mass index (BMI) 
and were more often smokers (Table 1). We observed 27.9% 
higher fibrinogen and 126% higher D-dimer, together with 
19.5% higher MP-TF activity in patients compared with 
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controls (Table 2). Lung cancer patients with ED com-
pared to those with LD were characterized by 91.7% higher 
D-dimer levels (p < 0.0001) and 42.8% higher MP-TF activ-
ity (p = 0.014; Table 3).
Cotinine serum levels in lung cancer patients
Smoking intensity in lung cancer patients was high (median, 
40, range 25–45 pack-years), especially in those with 
SCLC compared with the remainder [40 (30–50) vs. 30 
(20–4) pack-years, p = 0.0073]. Cotinine was detected in 
95% of lung cancer patients, and its levels were higher in 
patients who declared current smoking compared to those 
who declared former smoking (n = 55) [66.5 (59–74) vs. 
33 (12–58) ng/ml, p < 0.0001], and never smoking (n = 13) 
[66.5 (59–74) vs. 5 (1–8) ng/ml, p < 0.0001), respectively. 
Cotinine serum levels [median, 58.5 (23–70) ng/ml] corre-
lated with the smoking pack-years (r = 0.28, p = 0.0014) and 
fibrinogen (r = 0.27, p < 0.001), but showed no associations 
with demographic variables or clinical factors.
Thrombin generation
Lung cancer patients had 87% longer lag time and 100% 
higher peak thrombin generated than controls, while time to 
thrombin peak (TTPeak) and endogenous thrombin potential 
(ETP) were similar in both groups (Table 2). There were no 
associations of thrombin generation with demographic or 
clinical factors, including CAD or diabetes.
Thrombin generation variables were similar among 
patients with different histological types of lung cancer and 
in those with LD or ED (Table 3). Lag time and TTPeak 
Table 1  Baseline characteristics of the control subjects and lung can-
cer patients
Data are given as number (percentage), mean ± SD, or median (inter-
quartile range)
COPD chronic obstructive lung disease, CAD coronary artery dis-
ease, HF heart failure, ACEI, angiotensin-converting enzyme inhibi-
tors
Variable Control 
subjects 
(n = 90)
Lung cancer 
patients 
(n = 150)
P value
Age, years 64.1 ± 7.2 64.2 ± 7.0 0.92
Male, n (%) 69 (76.7) 102 (68.0) 0.15
Body mass index, kg/m2 27.3 ± 3.5 25.2 ± 4.8 < 0.001
Clinical characteristics, n (%)
 Current smoking, n (%) 9 (10.0) 82 (54.7) < 0.001
 Previous stroke, n (%) 8 (8.9) 6 (4.0) 0.12
 CAD, n (%) 19 (21.1) 23 (15.3) 0.25
 Arterial hypertension, n 
(%)
50 (55.6) 71 (47.3) 0.22
 Diabetes, n (%) 7 (7.8) 18 (12.0) 0.30
 COPD, n (%) 12 (13.3) 19 (12.7) 0.88
Table 2  Laboratory tests and 
fibrin clot variables in control 
subjects and lung cancer 
patients
Data are given as mean ± SD or median (interquartile range)
RBC red blood cells, WBC white blood cells, MP-TF Tissue Factor-bearing microparticles procoagulant 
activity, Ks fibrin clot permeability, ΔAbs (405 nm) maximum absorbance of fibrin gel at 405 nm, TTPeak 
time to thrombin peak, ETP endogenous thrombin potential
*Adjusted for body mass index, creatinine, glucose, and fibrinogen
Variable Control subjects (n = 90) Lung cancer patients (n = 150) P value*
RBC,  106/µl 4.35 ± 0.4 4.47 ± 0.5 0.87
WBC,  103/µl 6.0 (5.2–7.2) 9.2 (7.4–12.0) < 0.001
Platelets,  103/µl 237 (198–303) 309 (244–366) < 0.001
Hemoglobin, g/dl 13.9 ± 1.4 12.8 ± 1.6 < 0.001
Glucose, mM 4.7 (4.4–5.0) 5.3 (4.9–5.9) < 0.001
Creatinine, µM 68 (62–77) 74 (62–84) 0.064
Fibrinogen, g/l 2.47 (2.24–3.08) 3.16 (2.70–3.95) < 0.001
D-dimer, ng/ml 218 (193–261) 493 (308–893) < 0.001
MP-TF activity, pg/ml 1.33 (0.98–1.9) 1.59 (1.00–2.40) 0.020
Ks,  10− 9cm2 9.2 (7.5–9.9) 6.7 (5.8–7.5) < 0.001
Lag phase, s 43.16 ± 4.56 39.65 ± 4.06 0.006
ΔAbs (405 nm) 0.80 (0.75–0.86) 0.85 (0.80–0.89) 0.69
Clot lysis time, min 76.9 ± 14.3 97.3 ± 16.8 < 0.001
Lag time, s 631 (566–729) 1180 (1031–1453) < 0.001
Peak thrombin generated, nM 73 (60–159) 146 (105–221) 0.001
TTPeak, s 2006 (1654–2253) 2134 (1854–2519) 0.098
ETP, nM*s 82,836 ± 27,965 95,423 ± 38,411 0.23
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correlated with platelet count (r = 0.25, p = 0.0022 and 
r = 0.26, p = 0.0019, respectively), while peak thrombin 
generated and ETP showed associations with WBC count 
(r = 0.20, p = 0.014 and r = 0.18, p = 0.028). We observed no 
associations of thrombin parameters with MP-TF or cotinine.
Fibrin clot properties
Lung cancer patients had 27.2% lower  Ks, 8.1% shorter tur-
bidimetric lag phase, and 26.5% longer CLT than control 
subjects (Fig. 1), while ΔAbs did not differ between both 
groups (Table 2). Intergroup differences in fibrin variables 
remained significant after adjustment for body mass index, 
creatinine, glucose, and fibrinogen. Thinner plasma fibrin 
fibers were observed in lung cancer patients compared with 
controls (87.1 ± 9.9 vs. 116.7 ± 13.2 nm, p < 0.0001; Fig. 2).
Patients with lung cancer and concomitant CAD had 6.3% 
longer CLT than those without CAD [102 (95–118) vs. 96 
(85–106) min, p = 0.026]. There were no differences in fibrin 
clot properties regarding other clinical or demographic vari-
ables (data not shown).
Interestingly, lung cancer patients who declared smoking 
intensity > 20 pack-years had 6.8% lower  Ks compared with 
the remainder (6.5 ± 1.0 vs. 7.0 ± 1.0 × 10−9cm2, p = 0.026). 
Fibrin features were similar among patients with different 
histological types of lung cancer and in patients with ED 
compared with those with the LD (Table 3). We observed 
no associations of fibrin variables with MP-TF or plasma 
Table 3  Characteristics of lung cancer patients with regard to the histological type of cancer and the cancer stage
Data are given as mean ± SD or median (interquartile range)
SCLC small cell lung cancer, NSCLC non-small cell lung cancer, NOS carcinoma not otherwise specified carcinoma, LD limited disease, ED 
extended disease, for other abbreviations see Table 2
Variable Histological type of cancer Cancer stage
SCLC (n = 61) NSCLC
Squamous cell 
cancer (n = 37)
Adenocarcinoma 
(n = 39)
NOS carcinoma 
(n = 13)
LD (n = 58) ED (n = 92)
Age, years 65 (60–68) 65 (61–68) 63 (58–67) 63 (59–66) 64 ± 7 65 ± 7
Male, n (%) 39 (64) 26 (70) 27 (69) 10 (77) 39 (67) 63 (69)
Body mass index, 
kg/m2
24.9 (22.4–28.7) 24.5 (21.1–27.6) 25.0 (21.7–26.8) 24.1 (22.0–25.6) 25.9 ± 4.8 24.8 ± 4.8
Current smoking, 
n (%)
35 (57) 19 (51) 19 (49) 9 (69) 32 (55) 50 (54)
RBC,  106/µl 4.53 (4.08–4.80) 4.39 (4.11–4.60) 4.38 (4.15–5.0) 4.80 (4.47–5.10) 4.5 ± 0.5 4.5 ± 0.5
WBC,  103/µl 8.96 (7.28–11.3) 9.40 (7.88–12.30) 8.81 (6.73–11.40) 12.90 (8.99–16.50) 9.30 (7.02–11.70) 9.11 (7.59–12.40)
Platelets,  103/µl 300 (215–342) 334 (267–413) 299 (237–374) 315 (254–434) 321 (270–380) 292 (226–364)
Hemoglobin, g/dl 13.2 (11.6–14.0) 12.4 (11.4–13.6) 12.8 (12.2–14.3) 12.9 (12.4–13.9) 13.0 (12.2–14.0) 12.7 (11.6–14.0)
Glucose, mM 5.2 (4.9–5.6) 5.2 (5.0–7.0) 5.6 (5.1–6.0) 6.4 (5.2–7.6) 5.2 (4.9–5.8) 5.4 (5.0–6.1)
Creatinine, µM 74 (62–86) 69 (54–88) 74 (63–82) 70 (58–79) 72 (62–84) 74 (62–85)
Fibrinogen, g/l 3.13 (2.70–3.90) 3.32 (2.61–4.0) 3.38 (3.04–4.10) 2.90 (2.55–3.00) 3.11 (2.65–3.80) 3.22 (2.71–4.10)
D-dimer, ng/ml 446 (254–691) 445 (357–1167) 663 (351–1174) 491 (303–572) 324 (238–494) 621 (399–1231)
MP-TF activity, 
pg/ml
1.43 (0.93–2.18) 1.63 (1.00–2.52) 1.91 (1.24–2.47) 1.31 (1.08–1.43) 1.31 (0.89–2.17) 1.87 (1.21–2.48)
Cotinine, ng/ml 63 (33–72) 45 (22–70) 46 (18–70) 57 (49–59) 57 (27–67) 61 (23–73)
Ks,  10− 9cm2 6.8 (5.8–7.4) 6.2 (5.8–7.5) 6.5 (5.8–7.0) 7.8 (6.5–7.9) 6.5 ± 1.0 6.8 ± 1.1
Turbidimetric lag 
phase, s
39 (37–42) 40 (38–43) 39 (36–40) 39 (38–42) 39 (37–43) 40 (37–42)
ΔAbs (405 nm) 0.85 (0.81–0.90) 0.86 (0.80–0.90) 0.85 (0.80–0.90) 0.90 (0.80–0.90) 0.85 ± 0.06 0.85 ± 0.06
Clot lysis time, min 94 (84–104) 99 (89–107) 101 (91–111) 96 (81–104) 99 (85–107) 98 (89–107)
Lag time, s 1210 (1047–1418) 1204 (1067–1574) 1151 (924–1372) 1011 (927–1219) 1229 (1050–1485) 1135 (979–1379)
Peak thrombin 
generated, nM
138 (102–188) 161 (130–233) 139 (97–208) 209 (154–273) 154 (116–213) 144 (100–224)
TTPeak, s 2139 (1854–2614) 2243 (1996–2566) 2115 (1749–2490) 1949 (1749–2134) 2215 (1915–2552) 2105
(1825–2504)
ETP, nM*s 90,767 (62,099–
111,559)
90,699 (65,796–
128,937)
94,234 (70,243–
128,012)
123,087 (83,329–
144,520)
94,687 (67,917–
119,202)
91,221 (63,066–
129,663)
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D-dimer. There was a weak positive correlation between 
CLT and ETP in cancer patients (r = 0.18, p = 0.029), but 
no other associations between thrombin generation param-
eters and fibrin clot variables were noted. Cotinine levels 
were associated with ΔAbs (r = 0.20, p = 0.016) and  Ks 
(r = − 0.50, p < 0.0001).
On univariate analysis, the presence of HF (n = 8, 5.3%), 
hyperlipidemia (n = 23, 15.3%), and cotinine levels were 
associated with a large density of plasma fibrin clots defined 
as the lower quartile of  Ks [< 5.80 × 10−9  cm2; odds ratio 
(OR) = 12.78, 95% confidence interval (CI) 2.44–66.82, 
p = 0.0025, OR 2.76, 95% CI 1.07–7.12, p = 0.036, and 
OR 1.027 per 1 ng/ml of cotinine level increase, 95% CI 
1.011–1.045, p = 0.0013, respectively] in lung cancer 
patients. In multivariate analysis, the increase in cotinine 
level independently predicted the lower quartile of  Ks (OR 
1.21 per 10 ng/ml, 95% CI 1.02–1.46, p = 0.037). HF was 
associated with hypofibrinolysis defined as the upper quar-
tile of CLT (≥ 107 min) on univariate and multivariate 
regression analyses (OR 6.22, 95% CI 1.41–27.53, p = 0.016, 
and OR 5.83, 95% CI 1.22–27.90, p = 0.027, respectively).
Discussion
We demonstrated that the prothrombotic plasma clot pheno-
type, including faster formation of fibrin clots, reduced fibrin 
network porosity, and impaired clot lysability, characterizes 
patients with advanced lung cancer. All the differences 
between the groups were observed also after adjustment for 
fibrinogen, a major determinant of clot properties, which 
was increased in cancer patients as expected. These pro-
thrombotic alterations showed no relationship with increased 
plasma D-dimer or thrombin generation, except the weak 
association between CLT and ETP, suggesting the impact of 
other factors on fibrin clot structure and function in cancer. 
Of note, there were no differences in the thrombin generation 
or fibrin properties between patients with disseminated vs. 
locally advanced inoperable lung cancer. Our study provides 
evidence that a hypercoagulable state observed in advanced 
lung cancer patients involves unfavorably altered structural 
and functional characteristics of fibrin clots, which might 
implicate difficulties in effective thromboprophylaxis and 
have practical implications in thrombotic risk assessment 
among cancer patients given data on a value of  Ks and CLT 
in predicting thromboembolic events [32, 33].
Fig. 1  Fibrin clot permeabil-
ity (a) and clot lysis time (b) 
in lung cancer patients and 
controls
Fig. 2  Representative scanning electron microscopy (SEM) images of 
fibrin networks in control (a) and lung cancer patient (b). Magnifica-
tion, 5000x; fibrinogen concentration, 3 g/L
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We found that current cigarette smoking has the most 
potent effect on clot density tested in vitro. Our study dem-
onstrated that active smoking is associated with unfavora-
bly altered plasma clot properties, including  Ks and ΔAbs, 
which exceed beyond potential effects of higher thrombin 
generation or MP-TF activity. Barua et al. have demon-
strated that acute cigarette smoke exposure in healthy sub-
jects impaired clot lysis ability measured in whole blood 
using thromboelastography by 23.9% and 21.6% compared 
to nonsmokers or with smokers after an overnight abstinence 
from smoke exposure [21]. Previously, we have reported 
that plasma fibrin clots prepared from plasma of apparently 
healthy smokers were characterized by 21.2% reduced  Ks 
and 35.4% prolonged fibrinolysis when compared to never-
smokers [34]. Interestingly, smokers with diagnosed CAD 
had 24% lower fibrin porosity than healthy smokers [34]. In 
the current study, active smoking was independently asso-
ciated with the compact clot structure reflected by low  Ks 
in lung cancer patients. This finding suggests that smok-
ing has an incredibly strong prothrombotic effect in lung 
cancer. Cotinine level, as a marker of smoking exposure, 
showed that most of the so-called former smokers are still 
smoking and provided false information. A recent meta-
analysis indicated that the proportion of patients with lung 
cancer who continue to smoke after diagnosis ranged from 
6 to 83% [35]. Mechanisms behind the association between 
smoking and fibrin clot properties in cancer patients remain 
to be established; however, most likely increased oxidative 
stress contributes to our observation [36]. Oxidative stress 
reflected by 8-epi-prostaglandin  F2α was enhanced in heavy 
smokers compared to never-smokers and strongly correlated 
with impaired fibrin clot properties in the former group [34]. 
The current study provides new insights into a hyperco-
agulable state in lung cancer, suggesting altered fibrin clot 
structure largely determined by the smoking status which 
is potent enough to preserve its impact on fibrin properties 
even in the presence of strong cancer-associated activation 
of blood coagulation.
Since fibrin clot variables in advanced lung cancer 
patients were similar to those reported in subjects with 
digestive tract cancer [22], the present study suggests that 
the prothrombotic clot phenotype could be a common feature 
of patients with various solid tumors. Indeed, Shoji et al. 
have shown that deposits of crosslinked fibrin occur within 
the stroma of 80% lung tumors [37] and can enhance cell 
proliferation, neovascularization, and protect tumor tissue 
by making an impermeable barrier [38]. Clinical implica-
tions of these observations remain to be established not only 
in terms of thromboembolic risk but also the disease itself. 
Previous studies demonstrated that cancer is associated with 
elevated platelet count, MP-TF activity, thrombin genera-
tion, and D-dimer [39]. We confirmed these observations. 
There is evidence that disturbed hemostasis plays a role in 
the metastatic capacity of solid tumors [40]. Increased acti-
vation of the blood coagulation along with the subsequent 
fibrinolysis evidenced in our cohort of lung cancer patients 
by higher MP-TF activity and thrombin leads to elevated 
D-dimer levels in patients with ED, related to poor prognosis 
in several studies on patients with solid tumors, including 
lung cancer [41]. These observations are in line with the 
study by Zhang et al. [42]. Thrombin generation markers 
and D-dimer have been shown to be implicated in the meta-
static potential of various cancers [43]. In addition, throm-
bin and TF have been postulated to represent key mediators 
of cancer-related thrombosis in general [44]. However, we 
expanded the published data by demonstrating that fibrin 
is another important contributor to thrombotic tendency in 
cancer, and this feature is largely unrelated to the previously 
reported prothrombotic alterations. The current study pro-
vides additional evidence that a thrombotic potential of TF-
bearing MPs might contribute to the multifactorial hyper-
coagulability in lung cancer patients, however, without any 
clear association with fibrin characteristics in the advanced 
inoperable disease. Our study indicates that the cancer-
related prothrombotic clot phenotype cannot be explained 
by elevated fibrinogen or increased thrombin formation. 
Although these two factors are well known as those render-
ing the plasma fibrin clot more prothrombotic [19, 20], we 
found only a week association between CLT and ETP, but 
differences between cancer and control groups remained sig-
nificant after adjustments. It might be speculated that other 
factors disturb associations between thrombin generated and 
fibrin properties. Identification of its determinants deserves 
further investigation.
This study has several limitations. First, the sample size 
was limited. The study was, however, adequately powered to 
detect intergroup differences in clot variables, although the 
subgroup analyses should be interpreted with caution. Sec-
ond, we did not measure several potential fibrin clot modi-
fiers including homocysteine, lipoprotein(a), and fibrinolysis 
inhibitors [45], but their effects are likely to be of minor 
importance in cancer patients.
In conclusion, advanced lung cancer is associated with 
impaired plasma clot characteristics. Our study provides 
evidence for a strong effect of cigarette smoking on fibrin-
related variables despite the advanced lung cancer. Thus, 
smoking might be a key modulator of prothrombotic clot 
alterations in this disease. Clinical relevance of the current 
findings remains to be explored.
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